JENKEM(688356)2022-04-27 16:00Financial Performance - The company's revenue for Q1 2022 reached ¥100,845,422.03, representing a 44.23% increase compared to the same period last year[6] - Net profit attributable to shareholders was ¥52,338,062.73, reflecting a growth of 45.41% year-over-year[6] - Basic earnings per share (EPS) for the period was ¥0.87, up by 45.00% from the same quarter last year[6] - The company achieved a revenue of 100.84 million yuan in Q1 2022, representing a year-over-year growth of 44.23%[22] - Net profit attributable to shareholders reached 52.34 million yuan, up 45.41% compared to the previous year[22] - The company's operating profit for Q1 2022 was ¥59,295,556.46, an increase of 41.5% compared to ¥41,925,586.26 in Q1 2021[29] - Total comprehensive income for Q1 2022 was ¥51,952,638.01, compared to ¥35,552,598.07 in Q1 2021, reflecting a growth of 46%[29] Cash Flow - The net cash flow from operating activities surged to ¥45,349,764.61, a significant increase of 626.35% compared to the previous year[6] - Cash inflow from operating activities totaled ¥98,319,856.82 in Q1 2022, significantly higher than ¥43,551,510.57 in Q1 2021, marking a 125.5% increase[29] - The net cash flow from operating activities for Q1 2022 was ¥45,349,764.61, compared to ¥6,243,487.18 in Q1 2021, indicating a substantial improvement[31] - Cash flow from investing activities showed a net outflow of ¥8,644,110.42 in Q1 2022, an improvement from a net outflow of ¥283,369,778.66 in Q1 2021[31] - The company reported cash and cash equivalents of ¥263,039,542.62 at the end of Q1 2022, up from ¥432,074,402.33 at the end of Q1 2021[31] Research and Development - Total R&D investment amounted to ¥19,130,957.99, marking a 213.46% increase year-over-year, with R&D expenses accounting for 18.97% of revenue[9] - Research and development expenses increased by 213.46% year-over-year, reflecting the company's commitment to advancing its projects[22] - The company plans to continue expanding its R&D efforts and product offerings to sustain growth in the upcoming quarters[12] - The company continues to invest in the development of new products, including PEG-irinotecan and other projects, to enhance its R&D pipeline[22] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 5,385, with the largest shareholder holding 14,866,610 shares[14] - The company adjusted the grant price of its restricted stock incentive plan from 41.18 yuan to 40.75 yuan per share[22] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,160,654,182.59, a 5.40% increase from the end of the previous year[9] - The total assets of the company amounted to 1.16 billion yuan as of March 31, 2022, compared to 1.10 billion yuan at the end of 2021[25] - The company's total liabilities stood at 54.38 million yuan, an increase from 49.55 million yuan in the previous year[27] Revenue Breakdown - The main business revenue grew significantly, with product sales revenue at 90.14 million yuan, a 41.63% increase year-over-year[22] - Domestic sales revenue surged to 28.57 million yuan, marking a 93.80% increase from the same period last year[22] - The company reported a significant increase in technical service revenue, which reached 1.06 million yuan, up 71.64% year-over-year[22]